Australia Liquid Biopsy Market Size & Outlook, 2025-2033
The liquid biopsy market in Australia is expected to reach a projected revenue of US$ 129.4 million by 2033. A compound annual growth rate of 13.6% is expected of Australia liquid biopsy market from 2026 to 2033.
In terms of revenue, Australia accounted for 0.3% of the global liquid biopsy market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China liquid biopsy market is projected to lead the regional market in terms of revenue in 2033.
South Korea is the fastest growing regional market in Asia Pacific and is projected to reach USD 44.6 million by 2033.
The Australian liquid biopsy market is expected to grow significantly due to research collaborations and favorable government initiatives. In May 2022, the Australian Cancer Research Foundation (ACRF) launched the Child Cancer Liquid Biopsy Program for children with cancer.
Under this program, simple blood tests provide information about changes in a child with cancer through its journey and whether or not the child is supported well to treatment.
For instance, in November 2022, researchers at UNSW Sydney are focusing on developing less invasive and safer approaches to biopsy tumors, which is the next step in cancer monitoring and detection.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Liquid Biopsy Market Outlook will help companies and investors design strategic landscapes.
Blood Sample Based was the largest segment with a revenue share of 82.58% in 2025.
Horizon Databook has segmented the Australia liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2021 to 2033.
The Australian liquid biopsy market is expected to grow significantly due to research collaborations and favorable government initiatives. In May 2022, the Australian Cancer Research Foundation (ACRF) launched the Child Cancer Liquid Biopsy Program for children with cancer.
Under this program, simple blood tests provide information about changes in a child with cancer through its journey and whether or not the child is supported well to treatment.
For instance, in November 2022, researchers at UNSW Sydney are focusing on developing less invasive and safer approaches to biopsy tumors, which is the next step in cancer monitoring and detection.
Australia Liquid Biopsy Market Sample Type Outlook (Revenue, USD Million , 2021-2033)
Blood Sample Based
Others
Australia Liquid Biopsy Market Biomarker Outlook (Revenue, USD Million , 2021-2033)
Circulating Nucleic Acids
CTC
Exosomes/Microvesicles
Circulating Proteins
Australia Liquid Biopsy Market Technology Outlook (Revenue, USD Million , 2021-2033)
Multi-gene-parallel Analysis (NGS)
Single Gene Analysis (PCR Microarrays)
Australia Liquid Biopsy Market Application Outlook (Revenue, USD Million , 2021-2033)
Cancer
Reproductive Health
Others
Australia Liquid Biopsy Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals and Laboratories
Specialty Clinics
Academic and Research Centers
Others
Australia Liquid Biopsy Market Clinical Application Outlook (Revenue, USD Million , 2021-2033)
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring
Others
Australia Liquid Biopsy Market Product Outlook (Revenue, USD Million , 2021-2033)
Instruments
Consumables Kits and Reagents
Software and Services
Reasons to subscribe to Liquid Biopsy Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Liquid Biopsy Market Outlook databook
Our clientele includes a mix of Liquid Biopsy Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Liquid Biopsy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Liquid Biopsy Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.